Login to Your Account

Karo Bio Grosses $59.6M In Discounted Rights Offering

By Cormac Sheridan

Wednesday, May 16, 2007
With a deal for its preclinical treatment for tackling dyslipidemia, KB-5359, thought to be imminent, Karo Bio AB strengthened its hand in partnering negotiations by completing a discounted rights offering that grossed SEK406 million (US$59.6 million). The cash is intended to fund the company through 2009 and into 2010. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription